KSP 1007
Alternative Names: KSP-1007Latest Information Update: 15 Feb 2024
At a glance
- Originator Kitasato Institute; Sumitomo Dainippon Pharma
- Developer Kitasato Institute; Sumitomo Pharma; Sumitomo Pharma America
- Class Anti-infectives; Antibacterials
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bacterial infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
Most Recent Events
- 15 Feb 2024 Phase-I clinical trials in Intra-abdominal infections in Japan (unspecified route) before February 2024 (Sumitomo Pharma pipeline, February 2024)
- 15 Feb 2024 Phase-I clinical trials in Nosocomial pneumonia in Japan, USA (unspecified route) before February 2024 (Sumitomo Pharma pipeline, February 2024)
- 15 Feb 2024 Phase-I clinical trials in Urinary tract infections in Japan (unspecified route) before February 2024 (Sumitomo Pharma pipeline, February 2024)